Background Inflammatory bowel diseases [IBD]―ulcerative colitis and Crohn's disease―are
commonly treated with biologic drugs. However, only approximately two-thirds of patients …

The association between smoke habit and autoimmunity has been hypothesized a long time
ago. Smoke has been found to play a pathogenic role in certain autoimmune disease as it …

The advent of biological therapy has revolutionized inflammatory bowel disease (IBD) care.
Nonetheless, not all patients require biological therapy. Selection of patients depends on …

Primary nonresponse and primary nonremission are important limitations of tumor necrosis
factor (TNF) antagonists, occurring in 10% to 40% and 50% to 80% of patients with …

BACKGROUND & AIMS: Few data are available on effects of biologic therapies in patients
more than 65 years old with inflammatory bowel disease (IBD). We evaluated the risk and …

In the last decade, biologic agents, in particular anti-TNF agents such as infliximab,
adalimumab, and certolizumab have substantially extended the therapeutic armamentarium …

Despite all of the advances in our understanding of the pathophysiology of inflammatory
bowel disease (IBD), we still do not know its cause. Some of the most recently available data …

Abstract Background and Aim The biosimilar of infliximab, CT‐P13, has recently been
shown to be equivalent to infliximab in both efficacy and safety in the treatment of …

Infliximab, the chimeric monoclonal IgG1 antibody to tumour necrosis factor, is indicated for
refractory luminal and fistulizing Crohn's disease and extra‐intestinal manifestations of …

Aim The introduction of anti‐tumour necrosis factor (anti‐TNF; infliximab and adalimumab)
has changed the management of Crohn's perianal fistula from almost exclusively surgical …